Background
Methods
Patients and specimens
Parameters | CD44v2 | CD44v3 | CD44v4 | CD44v5 | CD44v6 | CD44v7 | CD44v8 | CD44v9 | CD44v10 | CD44s | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
+ | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | |
Gender | ||||||||||||||||||||
P-value | 0.379 | 0.379 | 0.956 | 0.68 | 0.956 | 0.178 | 0.956 | 0.956 | 0.322 | 0.379 | ||||||||||
Male/Female | 40/10 | 37/14 | 40/10 | 37/14 | 39/12 | 38/12 | 39/11 | 38/13 | 39/12 | 38/12 | 41/9 | 36/15 | 38/12 | 39/12 | 39/12 | 38/12 | 41/10 | 36/14 | 40/10 | 37/14 |
Age, years | ||||||||||||||||||||
P-value | 0.875 | 0.551 | 0.551 | 0.777 | 0.777 | 0.551 | 0.551 | 0.777 | 0.47 | 0.551 | ||||||||||
<65/≥65 | 36/14 | 36/15 | 37/13 | 35/16 | 37/13 | 35/16 | 35/15 | 37/14 | 37/14 | 35/15 | 37/13 | 35/16 | 37/13 | 35/16 | 37/14 | 35/15 | 38/13 | 34/16 | 37/13 | 35/16 |
Tumor location | ||||||||||||||||||||
P-value | 0.353 | 0.796 | 0.737 | 0.737 | 0.796 | 0.796 | 0.796 | 0.737 | 0.737 | 0.353 | ||||||||||
Head/Body,tail | 42/8 | 46/5 | 44/6 | 44/7 | 45/6 | 43/7 | 43/7 | 45/6 | 44/7 | 44/6 | 44/6 | 44/7 | 44/6 | 44/7 | 45/6 | 43/7 | 45/6 | 43/7 | 42/8 | 46/5 |
Tumor size, cm | ||||||||||||||||||||
P-value | 0.9 | 0.593 | 0.489 | 0.346 | 0.489 | 0.9 | 0.9 | 0.9 | 0.593 | 0.271 | ||||||||||
≤2/>2 | 19/31 | 20/31 | 18/32 | 21/30 | 18/33 | 21/29 | 17/33 | 22/29 | 18/33 | 21/29 | 19/31 | 20/31 | 19/31 | 20/31 | 20/31 | 19/31 | 21/30 | 18/32 | 22/28 | 17/34 |
Lymphatic invasion | ||||||||||||||||||||
P-value | 0.625 | 0.197 | 0.055 | 0.197 |
0.02
| 0.09 | 0.09 |
0.02
| 0.129 | 0.474 | ||||||||||
Neg/Pos | 27/23 | 30/21 | 25/25 | 32/19 | 24/27 | 33/17 | 25/25 | 32/19 | 23/28 | 34/16 | 24/26 | 33/18 | 24/26 | 33/18 | 23/28 | 34/16 | 25/26 | 32/18 | 30/20 | 27/24 |
Vascular invasion | ||||||||||||||||||||
P-value |
0.006
| 0.408 | 0.408 | 0.702 | 0.951 | 0.408 | 0.951 | 0.702 | 0.951 | 0.203 | ||||||||||
Neg/Pos | 30/20 | 43/8 | 38/12 | 35/16 | 35/16 | 38/12 | 37/13 | 36/15 | 37/14 | 36/14 | 38/12 | 35/16 | 36/14 | 37/14 | 36/15 | 37/13 | 37/14 | 36/14 | 39/11 | 34/17 |
Neural invasion | ||||||||||||||||||||
P-value | 0.875 | 0.875 | 0.777 | 0.3 | 0.875 | 0.777 | 0.551 | 0.245 | 0.875 | 0.47 | ||||||||||
Neg/Pos | 36/14 | 36/15 | 36/14 | 36/15 | 37/14 | 35/15 | 38/12 | 34/17 | 36/15 | 36/14 | 35/15 | 37/14 | 37/13 | 35/16 | 39/12 | 33/17 | 36/15 | 36/14 | 34/16 | 38/13 |
Duodenal invasion | ||||||||||||||||||||
P-value | 0.295 | 0.583 | 0.653 | 0.653 | 0.295 | 0.295 | 0.653 | 0.583 | 0.961 | 0.147 | ||||||||||
Neg/Pos | 38/12 | 43/8 | 39/11 | 42/9 | 40/11 | 41/9 | 41/9 | 40/11 | 43/8 | 38/12 | 38/12 | 43/8 | 41/9 | 40/11 | 42/9 | 39/11 | 41/10 | 40/10 | 43/7 | 38/13 |
Hepatic metastases | ||||||||||||||||||||
P-value | 0.484 |
0.042
|
0.049
| 0.172 |
0.049
|
0.049
|
0.042
|
0.049
|
0.049
|
0.049
| ||||||||||
Neg/Pos | 44/6 | 47/4 | 42/8 | 49/2 | 43/8 | 48/2 | 43/7 | 48/3 | 43/8 | 48/2 | 43/7 | 48/3 | 42/8 | 49/2 | 43/8 | 48/2 | 43/8 | 48/2 | 48/2 | 43/8 |
Differentiation | ||||||||||||||||||||
P-value | 0.808 | 0.1 | 0.507 | 0.124 | 0.202 | 0.927 | 0.491 | 0.696 | 0.428 |
0.028
| ||||||||||
Poor | 13 | 16 | 18 | 11 | 17 | 12 | 19 | 10 | 15 | 14 | 14 | 15 | 15 | 14 | 13 | 16 | 16 | 13 | 11 | 18 |
Middle | 32 | 31 | 26 | 37 | 29 | 34 | 27 | 36 | 29 | 34 | 31 | 32 | 29 | 34 | 32 | 31 | 29 | 34 | 31 | 32 |
Well | 5 | 4 | 6 | 3 | 5 | 4 | 4 | 5 | 7 | 2 | 5 | 4 | 6 | 3 | 6 | 4 | 6 | 3 | 8 | 1 |
Stage (UICC) | ||||||||||||||||||||
P-value | 0.837 | 0.109 | 0.057 | 0.135 |
0.008
| 0.286 | 0.061 |
0.027
| 0.143 |
0.028
| ||||||||||
IA/IB | 4/11 | 6/14 | 3/13 | 7/12 | 2/12 | 8/13 | 2/13 | 8/12 | 2/13 | 8/12 | 3/12 | 7/13 | 4/12 | 6/13 | 4/11 | 6/14 | 4/12 | 6/13 | 6/18 | 4/7 |
IIA/IIB | 9/20 | 6/20 | 4/22 | 11/18 | 5/24 | 10/16 | 5/23 | 10/17 | 3/25 | 12/15 | 5/23 | 10/17 | 3/23 | 12/17 | 3/25 | 12/15 | 4/23 | 11/17 | 4/19 | 11/21 |
III/IV | 0/6 | 0/5 | 0/8 | 0/3 | 0/8 | 0/3 | 0/7 | 0/4 | 0/8 | 0/3 | 0/7 | 0/4 | 0/8 | 0/3 | 0/8 | 0/3 | 0/8 | 0/3 | 0/3 | 0/8 |
Cell culture
Cell invasion assay
RNA extraction and quantitative real-time PCR
Calculating the optimized cut-off point for CD44v2-CD44v10 and CD44s
Statistical analysis
Results
Increased expression of CD44v and decreased expression of CD44s were associated with the invasion and metastatic potential of PCa
CD44v6+, CD44v9+ and CD44s− may be associated with poor prognosis in pancreatic carcinoma
CD44v6+, CD44v9+ and CD44s− are key factors that affect the survival of pancreatic carcinoma patients
CD44v6+/CD44s− expression was an independent risk factor associated with the OS rate of pancreatic carcinoma patients
Variables | n | Median survival time (months) | 2-year survival rate (%) | P-value |
---|---|---|---|---|
Age (years) | 0.545 | |||
< 65 | 53 | 12 | 20.0 | |
≥65 | 22 | 13 | 20.2 | |
Gender | 0.793 | |||
Female | 16 | 10 | 12.5 | |
Male | 59 | 12 | 22.5 | |
Tumor size (cm) | 0.230 | |||
≤2 | 28 | 12 | 28.0 | |
>2 | 47 | 11 | 15.9 | |
pN |
0.002
| |||
Negative | 39 | 14 | 28.2 | |
Positive | 36 | 10 | 10.8 | |
Pv |
0.045
| |||
Negative | 55 | 12 | 26.1 | |
Positive | 20 | 10 | 5.0 | |
Hepatic metastases |
0.000
| |||
Negative | 68 | 12 | 22.3 | |
Positive | 7 | 6 | 0 | |
Differentiation | 0.989 | |||
Poor | 21 | 11 | 25.8 | |
Moderate | 49 | 12 | 17.7 | |
Well | 5 | 10 | 20.0 | |
pStage (UICC) |
0.000
| |||
I | 24 | 16 | 33.3 | |
II | 44 | 11 | 15.9 | |
III,IV | 7 | 6 | 0 | |
CD44v6 expression |
0.010
| |||
Negative | 35 | 14 | 28.5 | |
Positive | 40 | 10 | 13.0 | |
CD44v9 expression |
0.047
| |||
Negative | 37 | 12 | 27.0 | |
Positive | 38 | 10 | 13.7 | |
CD44s expression |
0.032
| |||
Negative | 40 | 10 | 12.5 | |
Positive | 35 | 14 | 29.6 | |
CD44v6,v9 expression |
0.014
| |||
Negative | 40 | 13 | 27.3 | |
Positive | 35 | 10 | 12.0 | |
CD44v6,s expression |
0.000
| |||
Negative | 53 | 13 | 29.0 | |
Positive | 22 | 7 | 0 | |
CD 44v9,s expression |
0.000
| |||
Negative | 53 | 13 | 29.0 | |
Positive | 22 | 7 | 0 |
Independent factors | Univariate P | Multivariate P | Hazard ratio | 95% Confidence interval |
---|---|---|---|---|
Pn (Neg/Pos) | 0.002 |
0.002
| 2.313 | 1.376-3.889 |
pv (Neg/Pos) | 0.045 | 0.370 | 1.342 | 0.705-2.557 |
Hepatic metastases (Neg/Pos) | 0.000 | 0.051 | 2.558 | 0.998-6.555 |
pStage (I/II/III, IV) | 0.000 | 0.925 | 1.041 | 0.450-2.407 |
CD44v6 expression (Neg/Pos) | 0.010 | 0.281 | 1.869 | 0.600-5.824 |
CD44v9 expression (Neg/Pos) | 0.047 | 0.718 | 0.748 | 0.155-3.603 |
CD44s expression (Neg/Pos) | 0.032 | 1.000 | 1.000 | 0.437-2.287 |
CD44v6,v9 expression (Neg/Pos) | 0.014 | 0.809 | 0.809 | 0.146-4.486 |
CD44v6,s expression (Neg/Pos) | 0.000 |
0.003
| 2.602 | 1.390-4.870 |
CD44v9,s expression (Neg/Pos) | 0.000 | 0.810 | 0.808 | 0.142-4.587 |